Teva Highlights Long-Term Success of Deutetrabenazine for Tardive Dyskinesia
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has made an important announcement regarding its treatment, deutetrabenazine, which shows impressive long-term efficacy and safety for patients dealing with Tardive Dyskinesia (TD). This finding comes from the European cohort of the RIM-TD open-label extension (OLE) study, indicating that patients experienced consistent improvements in TD symptoms over a three-year duration.
What is Tardive Dyskinesia?
Tardive Dyskinesia is a troubling movement disorder that affects about 15% to 25% of individuals receiving antipsychotic treatment for various mental health issues, such as schizophrenia and bipolar disorder. The condition typically results in repetitive, involuntary movements that can be socially stigmatizing and disabling, significantly diminishing the quality of life for those affected.
Insights from the RIM-TD Study
The RIM-TD study provides a thorough analysis of patients who had participated in several phase 3 trials of deutetrabenazine, namely the ARM-TD and AIM-TD studies. In this long-term research, treatment success was determined by whether participants felt 'much improved' or 'very much improved' through standardized global assessments. Remarkably, 65% of participants met this success criterion using the Clinical Global Impression of Change (CGIC), while 56% reached it according to the Patient Global Impression of Change (PGIC).
Expert Opinions on the Findings
During the recent European College of Neuropsychopharmacology Congress held in Milan, Dr. Krzysztof Duma, Teva's Associate Medical Director, emphasized the complexities involved in diagnosing and treating Tardive Dyskinesia. He pointed out that the positive results from the European cohort aligned with earlier findings from the broader population, offering crucial evidence that deutetrabenazine can serve as an effective treatment option.
The Challenge of Effective Treatment
Managing TD presents a unique challenge, particularly because many available treatments in Europe lack substantial clinical evidence and are often used beyond their intended purpose. In an attempt to ease TD symptoms, patients frequently lower their antipsychotic medication doses, which, unfortunately, can exacerbate their underlying psychiatric conditions.
Advocating for Improved Management Strategies
Dr. Pinar Kokturk, Vice President & Head of Medical Affairs at Teva, stressed the critical need for optimized treatment strategies for Tardive Dyskinesia, highlighting the absence of comprehensive guidelines throughout Europe. This appeal for better management aims to address the significant unmet needs linked to TD, ultimately intending to enhance patient outcomes.
Conclusion: Looking Ahead in Tardive Dyskinesia Treatment
With existing approval in the United States and various international markets, deutetrabenazine has demonstrated substantial benefits in improving motor functions in patients afflicted by Tardive Dyskinesia, as shown in extensive research, including ARM-TD and AIM-TD. This treatment goes beyond just addressing the immediate symptoms of TD; it reflects Teva's commitment to enhancing the overall health experiences of patients.
Frequently Asked Questions
What is Tardive Dyskinesia?
Tardive Dyskinesia is a chronic movement disorder that results in involuntary, repetitive movements, often due to extended use of antipsychotic medications.
What is deutetrabenazine?
Deutetrabenazine is a medication designed specifically for treating Tardive Dyskinesia by inhibiting the vesicular monoamine transporter type 2 (VMAT2), which helps lessen abnormal movements.
How effective is deutetrabenazine in treating TD?
Clinical studies have demonstrated that deutetrabenazine provides long-term improvements in TD symptoms, with many patients reporting significant relief throughout treatment.
Where can I find more information about Teva’s products?
For additional information on Teva Pharmaceutical Industries and its range of medications, please visit their official website.
What sets the RIM-TD study apart?
The RIM-TD study stands out as it focuses specifically on European patients who previously participated in pivotal phase 3 trials, offering targeted insights into the treatment effects of deutetrabenazine.
